Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2020

      Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020

      Conference Call and Live Audio Webcast Scheduled for Thursday, April 1, 2021 at 10:00 a.m. ET


      News provided by

      SWK Holdings Corporation

      Mar 31, 2021, 20:38 ET

      Share this article

      Share this article


      DALLAS, March 31, 2021 /PRNewswire/ --

      Corporate Highlights

      • Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers
      • Income producing assets as of December 31, 2020 reached an all-time high of $206.0 million, accompanied by strong credit trends
      • Closed a $9.0 million transaction in March 2021, deploying $7.1 million
      • Received two milestone payments from Cara Therapeutics totaling $5.0 million, with SWK retaining $3.0 million and the other $2.0 million being remitted to Enteris' prior owner. 

      Specialty Finance Segment Highlights:

      • For the fourth quarter of 2020, finance portfolio realized yield was 16.6%, compared to 20.4% for the fourth quarter of 2019
      • For the fourth quarter of 2020, finance portfolio effective yield was 13.8%, a 60 bps increase compared with 13.2% in the fourth quarter of 2019
      • Income producing assets increased 17.6% year over year to $206.0 million as of December 31, 2020
      • Total revenue for the quarter ended December 31, 2020 was $10.9 million, a 16.0% increase from $9.4 million for the quarter ended December 31, 2019
      • Core specialty finance business generated adjusted non-GAAP net income of $23.3 million
      • For the fiscal year 2020, SWK earned an 11.9% adjusted return on tangible financing book value
      • December 31, 2020 tangible financing book value per share was $15.84, a 7.5% increase from the prior year

      SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized companies, today provided a business update and announced its financial and operating results for the fourth quarter and full-year ended December 31, 2020.

      "2020 was a strong year for SWK fueled by our strategy of investing in differentiated, patent-protected, life sciences products and the small and mid-sized companies responsible for their development.  2020 results are highlighted by a 17.6% year-over-year growth in income producing assets to an all-time high of $206.0 million.  Importantly, this growth has been achieved in a disciplined fashion as evidenced by strong portfolio credit trends," stated Winston Black, Chairman and CEO of SWK Holdings. "We achieved this disciplined growth despite numerous challenges presented by the COVID-19 pandemic.  I am extremely proud of the resilience of the SWK team and our partners."

      Mr. Black continued, "During the fourth quarter, we closed two royalty monetizations and one loan financing, deploying $30.4 million. The transactions were with companies and products that address important market needs and provide value to patients, clinicians, and the broader healthcare system.  In March 2021, we closed a $9.0 million loan with Sincerus Pharmaceuticals, Inc., a 503B compounding pharmacy focused on dermatology customers.  We continue to source and evaluate numerous loan and royalty opportunities in-line with our historical experience."

      Mr. Black continued, "Our subsidiary Enteris BioPharma is working with our key partner, Cara Therapeutics, to advance its Oral KORSUVA™ program while progressing the three legs of its value creation strategy: 

      "First, Enteris' CEO Rajiv Khosla, PhD is focused on maximizing the potential of the company's proprietary Peptelligence® and ProPerma™ technologies, which enable the oral delivery of peptide and small molecule therapeutics. In this regard, Enteris' business development pipeline is very active, and we anticipate entry into several feasibility agreements over the coming quarters, with one already secured in 2021. Feasibility agreements are an important first step in building more comprehensive relationships with pharmaceutical partners.   

      "Second, Enteris anticipates initiating a clinical program for one of its internal assets targeting a niche indication which currently is treated by a cumbersome injection that limits patient compliance, which can lead to suboptimal patient outcomes.  SWK anticipates providing an update on this program later in 2021.   

      "Third, Enteris anticipates its newly expanded manufacturing facility, which includes a high potency API suite, will be cGMP operational in the coming weeks.  We believe high potency capabilities are an attractive and capacity constrained pharmaceutical manufacturing segment, as well as being complementary to Enteris' core peptide focus.  Enteris is in the early stages of marketing the facility and its capabilities to pharmaceutical companies.   

      "Finally, the partnership with Cara Therapeutics for Oral KORSUVA™ continues to advance as highlighted by Cara's positive public statements.  During 2020, SWK received $5.0 million of milestone payments with SWK retaining $3.0 million of the payments and the other $2.0 million being remitted to Enteris' prior owner.  We anticipate additional payments over the next several quarters, subject to the achievement of certain development milestones.  Oral KORSUVA™ is currently the subject of four separate clinical programs with multiple milestones anticipated throughout 2021, including topline results in the first half of 2021 from the Phase 2 atopic dermatitis clinical trial and initiation of a Phase 3 clinical trial for the treatment of pruritus in patients with stage III-IV chronic kidney disease expected in the second half of 2021, per recent guidance from Cara."

      Fourth Quarter 2020 Financial Results

      For the fourth quarter 2020, SWK reported total revenue of $10.9 million compared to $9.4 million for the fourth quarter 2019.  The $1.5 million net increase in revenue was primarily due to pharmaceutical development revenue generated by Enteris.

      Income before taxes for the fourth quarter 2020 totaled $3.3 million compared to $0.6 million for the same period of the previous year.  The year over year increase is primarily driven by a $2.4 million increase in pharmaceutical development revenue at Enteris, a $2.1 million decrease in expense for the amortization of Enteris-related intangibles, a $1.6 million decrease in impairment expense and a $2.4 million increase in contingent consideration expense.

      GAAP net income for the quarter ended December 31, 2020 totaled $4.6 million, or $0.36 per diluted share, compared to $8.8 million, or $0.68 per diluted share for the fourth quarter 2019.  For the fourth quarter 2020, non-GAAP adjusted net income was $7.5 million and non-GAAP adjusted net income for the specialty finance segment was $6.4 million, compared to $6.2 million for the fourth quarter 2019.

      Income producing assets (defined as finance receivables and corporate debt securities) totaled $206.0 million as of December 31, 2020.  This is a 17.6% increase compared with the income producing assets of $175.1 million as of December 31, 2019.

      Tangible financing book value per share totaled $15.84 as of December 31, 2020, a 7.5% increase from $14.74 as of December 31, 2019.  Management views tangible financing book value per share as a relevant metric to value the company's core specialty finance business.  Book value per share was $18.80 as of December 31, 2020 compared to $18.31 as of December 31, 2019.       

      Tables detailing SWK's financial performance for the fourth quarter 2020 are below.

      Portfolio Status

      During the fourth quarter 2020, the Company deployed $30.4 million through three transactions:

      1. $16.5 million to EyePoint Pharmaceuticals, Inc. to purchase the royalties payable to EyePoint under its license agreement with Alimera Sciences, Inc. for ILUVIEN®.
      2. $3.9 million to Trio Healthcare for the sale of certain royalty interests on a portfolio of ostomy products.
      3. $10.0 million first lien loan to Flowonix Medical, Inc., which markets the Prometra pump.

      At the end of the fourth quarter 2020, the weighted average projected effective yield of the finance receivables portfolio was 13.8%, including non-accrual positions, versus 13.2% as of the end of the fourth quarter in the previous year.  The projected effective yield is the rate at which income is expected to be recognized pursuant to the Company's revenue recognition policies, if all payments are received pursuant to the terms of the finance receivables and excludes non-interest earning assets such as warrants and equity investments.

      For the fourth quarter 2020, the realized yield of the finance receivables portfolio was 16.6%, versus 20.4% for the fourth quarter in the previous year.  The realized yield is inclusive of all fees, including all realized unamortized fees, amendment fees, and prepayment fees, and is calculated based on the simple average of finance receivables at the beginning and end of the period. The realized yield is greater than the effective yield due to actual cash collections being greater than modeled.

      Total portfolio investment activity for the three months ended December 31, 2020 and 2019 was as follows (in thousands):

      Portfolio Investment Activity

      Three Months Ended


      For the Year Ended

      (in thousands)

      December 31,


      December 31,


      2020


      2019


      2020


      2019

      Beginning Portfolio

      $    187,039


      $    180,417


      $    178,648


      $    169,919

      Early payoff

      (3,686)


      $     (10,000)


      (3,686)


      (33,500)

      Interest paid-in-kind

      (229)


      413


      2,145


      1,287

      Impairment expense and provision for credit losses

      -


      (1,600)


      (163)


      (2,209)

      Investment in finance receivables and marketable investments

      30,401


      10,000


      42,859


      51,198

      Loan discount and fee accretion

      385


      314


      1,904


      78

      Net unrealized gain (loss) on investments and warrants assets

      639


      314


      (1,254)


      2,068

      Principal payments received on investments

      (1,276)


      (152)


      (4,756)


      (4,829)

      Royalty (paydowns) accretion

      (868)


      (1,215)


      (3,371)


      (5,717)

      Warrant investments, net of cancellations

      -


      157


      79


      353

      Ending Portfolio

      $    212,405


      $    178,648


      $    212,405


      $    178,648

      Portfolio Updates Post Year End

      After the close of 2020, the Company closed a $9.0 million loan financing to Sincerus Pharmaceuticals, Inc. with $7.1 million funded at closing.

      Unfunded commitments totaled $1.9 million as of March 25, 2021.  

      Adjusted Non-GAAP Net Income

      Net income in accordance with GAAP for the three-month period ended December 31, 2020, was $4.6 million, or $0.36 per diluted share.

      The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the three-month periods ended December 31, 2020 and December 31, 2019.  The table eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and equity securities, amortization of Enteris intangible assets and loss on remeasurement of contingent consideration.

      (in thousands)

      Three Months Ended
      December 31,


      For the Year Ended
      December 31,


      2020


      2019


      2020

      2019

      Consolidated net income

      $

      4,644



      $

      8,785



      $ 5,202

      $ 23,828

      Add (Subtract): Income tax benefit

      (1,338)



      (8,157)



      (1,537)

      (6,986)

      Add (Subtract): Enteris amortization expense

      2,384



      4,495



      11,734

      4,816

      Add (Subtract): (Gain) loss on fair value of derivatives

      (565)



      (508)



      586

      (362)

      Add (Subtract): (Gain) loss on fair value of equity securities

      (75)



      144



      591

      144

      Add (Subtract): Remeasurement of contingent consideration

      2,436



      —



      4,400

      —

      Adjusted income before benefit from income taxes

      7,486



      4,759



      20,976

      21,440

      Adjusted benefit from income taxes

      —



      —



      —

      —

      Non-GAAP consolidated net income

      $

      7,486



      $

      4,759



      $20,976

      $21,440

      In the table above, management has deducted the following non-cash items: (i) change in the fair-market value of equities and warrants as mark-to-market changes are non-cash, (ii) income taxes as the Company has substantial net operating losses to offset against future income, (iii) amortization expense associated with Enteris intangible assets, and (iv) loss on remeasurement of contingent consideration.

      Specialty Finance Adjusted Non-GAAP Net Income

      The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the specialty finance business for the three-month period ended December 31, 2020.  The table eliminates expenses associated with the acquisition of Enteris, and Enteris operating losses.  The adjusted income before the provision for income taxes is derived in the table above and eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and equity securities.


      Three Months Ended
      December 31,


      For the Year Ended
      December 31,

      (in thousands)

      2020


      2019


      2020

      2019

      Adjusted income before benefit from income taxes

      $

      7,486


      $

      4,759


      $      20,976

      $      21,440

      Plus: Enteris acquisition expense

      —


      103


      —

      1,151

      Plus: Enteris operating income (loss) excluding depreciation and amortization

      (1,095)


      1,383


      2,283

      1,880

      Adjusted specialty finance income before provision for income taxes

      6,391


      6,245


      23,259

      24,471

      Adjusted benefit from income taxes

      —


      —


      —

      —

      Non-GAAP specialty finance net income

      $

      6,391


      $

      6,245


      $    23,259

      $   24,471

      Conference Call Information

      SWK Holdings will host a conference call and live audio webcast on Friday, April 1, 2021, at 10:00 a.m. ET, to discuss its corporate and financial results for the fourth quarter 2020. Interested participants and investors may access the conference call by dialing either:

      • (844) 378-6488 (U.S.)
      • (412) 317-1079 (international)

      An audio webcast will be accessible via the Investors Events & Presentations section of the SWK Holdings' website: https://swkhold.investorroom.com/events.  An archive of the webcast will remain available for 90 days beginning at approximately 11:30 a.m. ET, on April 1, 2021.

      Non-GAAP Financial Measures

      This release includes non-GAAP adjusted net income and non-GAAP specialty finance net income, which are not metrics that are compliant with generally accepted accounting principles in the United States (GAAP). 

      • Non-GAAP adjusted net income is adjusted for certain items (including (i) changes in the fair-market value of public equity-related assets and SWK's warrant assets as mark-to-market changes are non-cash, (ii) income taxes as the Company has substantial net operating losses to offset against future income, and (iii) depreciation and amortization expenses, primarily associated with the Enteris acquisition).
      • In addition to the adjustments noted above, non-GAAP specialty finance net income also excludes Enteris operating losses.
      • Tangible financing book value per share excludes the deferred tax asset, intangible assets, goodwill, Enteris PP&E, and contingent consideration associated with the Enteris transaction.
      • Adjusted return on tangible financing book value is calculated by dividing specialty finance division segment adjusted non-GAAP net income by Tangible financing book value.

      These non-GAAP measures may not be directly comparable to similar measures used by other companies in our industry, as other companies may define such measures differently. Management believes that these measures are useful to investors and management in understanding our ongoing operations and in analysis of ongoing operating trends and provides useful additional information relating to our operations and financial condition. These metrics should be considered in addition to, and not as a replacement for, the most comparable GAAP measure.

      About SWK Holdings Corporation
      SWK Holdings Corporation is a specialty finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. SWK also owns Enteris Biopharma, whose core Peptelligence® drug delivery technology creates oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its specialty finance business by actively building a wholly-owned portfolio of milestones and royalties through licensing activities.  Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

      Safe Harbor Statement
      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

      SWK HOLDINGS CORPORATION

      CONSOLIDATED BALANCE SHEETS

      (In thousands, except share data)



      December 31,


      2020


      2019

      Assets




      Current assets:




      Cash and cash equivalents

      $

      3,008



      $

      11,158


      Interest and accounts receivable, net

      1,911



      2,554


      Marketable investments

      1,210



      1,802


      Other current assets

      542



      783


      Total current assets

      6,671



      16,601






      Finance receivables, net

      204,491



      172,825


      Marketable investments

      241



      466


      Investment in TRT

      3,491



      —


      Deferred tax asset, net

      27,491



      25,780


      Warrant assets

      2,972



      3,555


      Intangible assets, net

      13,617



      25,113


      Goodwill

      8,404



      8,404


      Property and equipment, net

      5,211



      1,292


      Other non-current assets

      1,312



      640


      Total assets

      $

      273,901



      $

      254,372






      LIABILITIES AND STOCKHOLDERS' EQUITY




      Current liabilities:




      Accounts payable and accrued liabilities

      $

      3,652



      $

      3,061


      Revolving credit facility

      11,758




      —


      Total current liabilities

      15,410



      3,061






      Contingent consideration payable

      16,900



      14,500


      Warrant liability

      —



      76


      Other non-current liabilities

      1,079



      203


      Total liabilities

      33,389



      17,840






      Stockholders' equity:




      Preferred Stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

      —



      —


      Common stock, $0.001 par value; 250,000,000 shares authorized; 12,792,586 and 12,917,348 shares issued and outstanding at December 31, 2020 and 2019, respectively

      13



      13


      Additional paid-in capital

      4,430,924



      4,432,146


      Accumulated deficit

      (4,190,425)



      (4,195,627)


      Total SWK Holdings Corporation stockholders' equity

      240,512



      236,532


      Total liabilities and stockholders' equity

      $

      273,901



      $

      254,372


      SWK HOLDINGS CORPORATION

      CONSOLIDATED STATEMENTS OF INCOME

      (In thousands, except per share data)



      Year Ended December 31,


      2020


      2019

      Revenues




      Finance receivable interest income, including fees

      $

      30,800



      $

      30,117


      Pharmaceutical development

      5,903



      621


      Other

      9



      9


      Total revenues

      36,712



      30,747


      Costs and expenses:




      Provision for loan credit losses

      —



      2,209


      Impairment expense

      163



      —


      Pharmaceutical manufacturing, research and development expense

      4,268



      1,176


      General and administrative

      10,546



      7,430


      Depreciation and amortization expense

      12,091



      4,954


      Interest expense

      455



      338


      Change in fair value of acquisition-related contingent consideration

      4,400



      —


      Total costs and expenses

      31,923



      16,107


      Other (expense) income, net:




      Unrealized net (loss) gain on derivatives

      (586)



      362


      Unrealized net (loss) gain on equity securities

      (591)



      1,643


      Gain on sale of investments

      53



      197


      Income before income tax benefit

      3,665



      16,842


      Income tax benefit

      (1,537)



      (6,986)


      Consolidated net income

      $

      5,202



      $

      23,828






      Net income per share




      Basic

      $

      0.40



      $

      1.85


      Diluted

      $

      0.40



      $

      1.85


      Weighted Average Shares:




      Basic

      12,852



      12,906


      Diluted

      12,862



      12,911


      SWK HOLDINGS CORPORATION

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (in thousands)



      Year Ended December 31,


      2020


      2019

      Cash flows from operating activities:





      Consolidated net income

      $

      5,202



      $

      23,828


      Adjustments to reconcile net income to net cash provided by operating activities:






      Provision for loan credit losses

      —



      2,209


      Amortization of debt issuance costs

      188



      188


      Impairment expense

      163



      —


      Deferred income taxes

      (1,711)



      (7,100)


      Change in fair value of warrants

      586



      (362)


      Change in fair value of equity securities

      591



      (1,643)


      Gain on sale of investments

      (53)



      (197)


      Change in fair value of acquisition-related contingent consideration

      4,400



      —


      Loan discount amortization and fee accretion

      (1,983)



      (349)


      Interest paid-in-kind

      (2,145)



      (1,287)


      Stock-based compensation

      728



      530


      Interest income in excess of cash collected

      —



      (82)


      Depreciation and amortization

      12,091



      4,954


      Changes in operating assets and liabilities:




      Interest and accounts receivable

      643



      (214)


      Other assets

      (959)



      (205)


      Accounts payable and other liabilities

      1,527



      (1,734)


      Net cash provided by operating activities

      19,268



      18,536






      Cash flows from investing activities:




      Acquisition of business, net of cash acquired

      —



      (19,719)


      Cash received from settlement of warrants

      53



      —


      Proceeds from sale of investments

      —



      197


      Investment in equity securities

      —



      (159)


      Investment in finance receivables

      (42,859)



      (51,039)


      Repayment of finance receivables

      11,752



      43,980


      Corporate debt security principal payment

      62



      66


      Purchases of property and equipment

      (3,937)



      (48)


      Other

      (237)



      —


      Net cash used in investing activities

      (35,166)



      (26,722)






      Cash flows from financing activities:




      Repurchases of common stock, including fees and expenses

      (2,010)



      (883)


      Net proceeds and payments under credit facility

      11,758



      —


      Payment of acquisition-related contingent consideration

      (2,000)



      —


      Net cash provided by (used in) financing activities

      7,748



      (883)






      Net decrease in cash and cash equivalents

      (8,150)



      (9,069)


      Cash and cash equivalents at beginning of period

      11,158



      20,227


      Cash and cash equivalents at end of period

      $

      3,008



      $

      11,158






      Supplemental noncash flow activity:




      Warrants received in connection with finance receivables

      $

      79



      $

      353


      Fair value of common stock issued in lieu of employee cash bonuses

      $

      60



      $

      —


      Contingent consideration in connection with business combination

      $

      —



      $

      14,500











      SOURCE SWK Holdings Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.